Biocon Biologics to introduce three new biosimilars for cancer treatment

Biocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The company aims to expand access to vital cancer treatments. These biosimilars will offer cost-effective alternatives. Biocon Biologics will have one of the most comprehensive oncology portfolios. This move strengthens its commitment to patient care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f9msa6p
via IFTTT